Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.
about
Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent KinasesTFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic strokeCombinatorial libraries of bis-heterocyclic compounds with skeletal diversity.Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screeningSelectivity and potency of cyclin-dependent kinase inhibitors.Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.A Facile Approach to the Synthesis of 3,4-Disubstituted-2-Aminothiazolium Derivatives through the Use of A "Volatilizable" SupportCyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro ApproachesPeptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.Deregulated Cdk5 activity is involved in inducing Alzheimer's diseaseTau as a therapeutic target in neurodegenerative disease.Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse modelsComputational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.The CDK inhibitors in cancer research and therapy.Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors.CDK5 in oncology: recent advances and future prospects.Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.
P2860
Q27677453-B96A7F37-CCB1-4BDB-BC77-6E039302CFAAQ28397588-4300E324-9216-4902-9EB9-6B95AF9C4B18Q33371288-A3438A7A-5AAB-4B5C-82A9-2055233B67DEQ34625383-A50FB5F7-2791-4B47-A0DF-82BC6F851F69Q34651981-F912C354-ECA8-4C13-80D0-B471E12C0A66Q34706737-9695FE36-424C-4B96-9A4E-4E077BFA163AQ35098330-26F17267-51D4-4E09-801D-D9808B5D77ACQ36037996-1FEA9FC0-BF7D-4BB6-BB82-B30CA0BACF04Q36139197-75C56662-A35A-4A19-B218-A96180CB57A6Q36337052-159BFD51-025F-402B-80FE-9BA745C67BB7Q36482937-61F12B51-BE3F-44D8-A968-7FC7560464AAQ36494716-683263E1-9BDF-48B8-8158-1A5A39399189Q36970350-0F12E203-6E41-4455-B875-B2AFF2C2B382Q37048487-B7EE973C-8AC2-4064-820C-398F61ED7D37Q37503295-9CF252A1-F3A8-480F-87C0-4B9771AE6B1CQ37923861-6E09DF8E-8D20-4FAF-B107-5811EA5595F3Q42740762-4E8F6A36-0511-46BB-90F1-702223D65A41Q44045827-B8E00512-2E97-44FE-8D10-17282D956E7DQ47873426-2DA3F339-456B-4C9B-9136-3FF7EED0ED99Q54441914-1C526894-DE44-4B36-94E4-67A0E4C8E745
P2860
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@en
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@nl
type
label
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@en
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@nl
prefLabel
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@en
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@nl
P2093
P1476
Discovery and SAR of 2-aminoth ...... tment for Alzheimer's disease.
@en
P2093
Bonnie Tate
Christopher B Cooper
Christopher J Helal
John C Lucas
Kristin Kelly
Marcia Peterson
Mark A Sanner
Mavis Adam
Michael K Ahlijanian
Stanley Kupchinsky
P304
P356
10.1016/J.BMCL.2004.09.006
P407
P577
2004-11-01T00:00:00Z